Compare WDFC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDFC | EWTX |
|---|---|---|
| Founded | 1953 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 1995 | 2021 |
| Metric | WDFC | EWTX |
|---|---|---|
| Price | $231.76 | $40.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $270.00 | $39.00 |
| AVG Volume (30 Days) | 180.3K | ★ 1.1M |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 30.92 | N/A |
| EPS | ★ 5.02 | N/A |
| Revenue | ★ $488,109,000.00 | N/A |
| Revenue This Year | $8.23 | N/A |
| Revenue Next Year | $5.85 | N/A |
| P/E Ratio | $46.34 | ★ N/A |
| Revenue Growth | ★ 19.49 | N/A |
| 52 Week Low | $175.38 | $12.31 |
| 52 Week High | $298.90 | $48.40 |
| Indicator | WDFC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 52.30 |
| Support Level | $192.20 | $37.81 |
| Resistance Level | $249.89 | $43.93 |
| Average True Range (ATR) | 10.36 | 2.69 |
| MACD | -3.42 | -0.52 |
| Stochastic Oscillator | 2.07 | 29.06 |
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.